*

Hitt og þetta 30. júlí 2007

OctoPlus to release 2007 first half-year results on Friday 3 August

OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that it will release its 2007 first half-year results on Friday 3 August 2007, at 7:45 Central European Time (CET). OctoPlus will conduct a conference call on Friday 3 August at 10:00 AM CET, which will also be webcast. To participate in the conference call, please dial the following telephone number: +31 45 631 6901. After the presentation of the results, Joost Holthuis, CEO of OctoPlus and Hans Pauli, CFO, will be available to answer questions. The live audio webcast can be accessed via OctoPlus' website at www.octoplus.nl, and will be available for replay following the event. For further information, please contact: Rianne Roukema, Corporate Communications, +31 71 524 1071 About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines. Our pipeline consists of 5 products in preclinical and clinical development. Our lead product is Locteron(TM), a sustained-release formulation of interferon alfa for the treatment of chronic hepatitis C, which we are co-developing with Biolex Therapeutics. Locteron is in Phase IIa clinical development. Furthermore, our pipeline comprises a product for the treatment of chronic middle ear infection also in Phase II development, a sustained-release formulation of growth hormone in Phase I and two preclinical single-shot vaccines. In addition, OctoPlus is a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that we derive from rendering formulation and manufacturing services help to support our own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.